Type 2 Diabetes

Once-weekly exenatide formulation can provide as much benefit as the traditional twice-daily dosing.

High linoleic acid level could reduce type 2 risk by 43 percent, new study found.

Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.

New study finds incidence of thyroid disorders in people with diabetes no higher than than those without.

Canagliflozin may reduce the risk of major cardiovascular complication, but amputation risk is increased.

Second-line treatment is often initiated without evidence of recommended use of first-line treatment.

Recent meta-analysis conducted to address ideal amount of dietary carbohydrates in the management of T2DM.

By Guest Writer David Kliff, Diabetic Investor: As we were getting ready to disembark the plane when it arrived in Lisbon I asked a long-term consultant to the diabetes industry why he comes to EASD. “I like to come here because what they have here will show up in our country in two years” was his response. Given what we witnessed at EASD there isn’t much to look forward to in 2019.

Philadelphia youth see rise in diagnosis; especially for African Americans, by 70%.

Common osteoarthritis treatment may be beneficial in lowering HbA1c.